Last updated on April 16, 2014 at 14:14 EDT

Dr. Louis-Philippe Vezina Named as a Recipient of the 2012 Prix du Quebec

October 29, 2012

QUEBEC CITY, Oct. 29, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG; OTCQX:
MDCGF), a biopharmaceutical company focused on developing highly
effective and competitive vaccines based on proprietary manufacturing
technologies and Virus-Like Particles (VLPs), today announced that
Chief Scientific Officer and co-founder Dr. Louis-Philippe Vézina has
been named as a recipient of the 2012 Prix du Quebec. The Prix du
Quebec is the most prestigious award given by the Government of Québec
for those that have contributed to Quebec social and scientific
progress.  Dr. Vezina will receive the Lionel-Boulet award in science,
which recognizes contributions in the areas of innovation and
scientific development through contributions to the economic growth of

“I am honoured to be selected to receive the Prix du Quebec, and
sincerely thank the Government of Quebec for this recognition,” said
Dr. Louis-Philippe Vézina, Chief Scientific Officer of Medicago. “The
Company has made significant advancements in its pipeline of
plant-based biopharmaceutical product candidates. I share this award
with my mentors and colleagues in recognition of their dedication and
industry-leading vision.”

“On behalf of Medicago, I would like to congratulate Louis on this award
which is a testament to his contributions to science, Quebec and the
Company,” said Andy Sheldon, Chief Executive Officer of Medicago. “Our
team of 190 employees continue to demonstrate their commitment to work
towards the success of Medicago’s leading-edge technology.”

The Prix du Québec have existed in their current form since 1977. Each
year, the government attributes six such awards in the cultural field
and five in the scientific field. The purpose of this tribute is to
recognize the career of women and men who have demonstrated a passion
for their calling and creative or innovative spirit, and whose work has
contributed to the influence of Québec around the world and to the
evolution of Québec society in their respective fields. The awards will
be given at a ceremony on November 13, 2012, at the National Assembly
in Quebec City.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements or
forward-looking information for the purposes of applicable securities
laws and such statements and information are based upon current
expectations, which involve risks and uncertainties associated with
Medicago’s business and the environment in which the business operates.
Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking, including those identified
by the expressions “anticipate”, “believe”, “plan”, “estimate”,
“expect”, “intend”, and similar expressions to the extent they relate
to Medicago or its management. The forward-looking statements are not
historical facts, but reflect Medicago’s current expectations regarding
future results or events. Such statements include but are not limited
to statements about the DARPA project, achievement of milestones and
financial payments related to the DARPA project, and statements related
to the potential for the commercial-scale facility in North Carolina. 
These forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations, including the matters discussed
under “Risk Factors and Uncertainties” in Medicago’s Annual Information
Form filed on March 29, 2012, with the regulatory authorities. Medicago
assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those reflected
in the forward-looking statements.

SOURCE Medicago Inc.

Source: PR Newswire